Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast CancerGuillermo Villacampa, Tomás Pascual, Rodrigo Sánchez-Bayona et al.|JAMA Oncology|2024Cited by 77
Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysisGuillermo Villacampa, Tomás Pascual, Pablo Tolosa et al.|Cancer Treatment Reviews|2022Cited by 30
High Resolution Esophageal Manometry in Patients with Chagas Disease: A Cross-Sectional EvaluationAdrián Sánchez-Montalvá, Israel Molina, Anna Accarino et al.|PLoS neglected tropical diseases|2016Cited by 26
Abstract PD13-01: PD13-01 Elacestrant in postmenopausal women with estrogen receptor positive and HER2-negative early breast cancer: primary efficacy and safety analysis of the preoperative, window of opportunity SOLTI-1905-ELIPSE trialMaría Vidal, Meritxell Bellet Ezquerra, Tomás Pascual et al.|Cancer Research|2023Cited by 12
Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT studyPablo Tolosa, Eva Ciruelos, Tomás Pascual et al.|European Journal of Cancer|2025Cited by 10